USA - New York Stock Exchange - NYSE:IQV - US46266C1053 - Common Stock
The current stock price of IQV is 244.29 USD. In the past month the price increased by 6.5%. In the past year, price increased by 18.33%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 27.55 | 231.87B | ||
| DHR | DANAHER CORP | 30.55 | 166.39B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 196.3 | 59.65B | ||
| A | AGILENT TECHNOLOGIES INC | 26.49 | 41.90B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.15 | 30.05B | ||
| WAT | WATERS CORP | 31.45 | 23.78B | ||
| ILMN | ILLUMINA INC | 34.44 | 22.94B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.38 | 20.03B | ||
| MEDP | MEDPACE HOLDINGS INC | 42.87 | 17.27B | ||
| TEM | TEMPUS AI INC | N/A | 12.41B | ||
| RVTY | REVVITY INC | 21.5 | 11.68B | ||
| CRL | CHARLES RIVER LABORATORIES | 20.55 | 10.67B |
IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. The company is headquartered in Durham, North Carolina and currently employs 91,000 full-time employees. The company went IPO on 2013-05-09. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.
IQVIA HOLDINGS INC
2400 Ellis Road
Durham NORTH CAROLINA 27703 US
CEO: Ari Bousbib
Employees: 91000
Phone: 19199982000
IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. The company is headquartered in Durham, North Carolina and currently employs 91,000 full-time employees. The company went IPO on 2013-05-09. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.
The current stock price of IQV is 244.29 USD. The price increased by 1.56% in the last trading session.
IQV does not pay a dividend.
IQV has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
29 analysts have analysed IQV and the average price target is 258.38 USD. This implies a price increase of 5.77% is expected in the next year compared to the current price of 244.29.
IQVIA HOLDINGS INC (IQV) operates in the Health Care sector and the Life Sciences Tools & Services industry.
IQVIA HOLDINGS INC (IQV) has a market capitalization of 41.60B USD. This makes IQV a Large Cap stock.
ChartMill assigns a technical rating of 9 / 10 to IQV. When comparing the yearly performance of all stocks, IQV is one of the better performing stocks in the market, outperforming 79.35% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to IQV. While IQV belongs to the best of the industry regarding profitability, there are concerns on its financial health.
Over the last trailing twelve months IQV reported a non-GAAP Earnings per Share(EPS) of 11.63. The EPS increased by 7.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.07% | ||
| ROA | 4.47% | ||
| ROE | 20.83% | ||
| Debt/Equity | 2.08 |
29 analysts have analysed IQV and the average price target is 258.38 USD. This implies a price increase of 5.77% is expected in the next year compared to the current price of 244.29.
For the next year, analysts expect an EPS growth of 7.78% and a revenue growth 5.28% for IQV